SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as traders speculate on potential near-term catalysts related to cannabis rescheduling following comments from a key political figure. The community is closely watching for further developments, with some expecting a possible short squeeze and others debating the long-term fundamentals of the stock. Broader discussions include the potential impact on the cannabis industry, particularly for veterans and medical research.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its recent surge, driven by excitement around its merger and potential in the robotics sector. Community members are actively discussing potential squeezes and price targets, while acknowledging the stock's volatility and low float. Bullish sentiment seems strong, with many hoping it can continue its momentum.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors digest the company's weaker-than-expected 2026 outlook, particularly concerning COVID-19 drug demand and patent expirations. The community is actively discussing the potential for dividend cuts and the need for a new growth engine beyond COVID-related revenue. Some investors are taking a long-term view, focusing on the dividend yield and potential upside from the company's pipeline.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial is trending due to a swing to profitability revealed in their Q2 earnings filing, which has sparked a surge in intraday trading. The community is discussing the potential for a turnaround squeeze, citing high short interest and a low float, drawing parallels to CVNA's past performance. Positive catalysts and debt restructuring are also key talking points.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending due to increased community excitement around the project's mission to disrupt traditional retirement systems. The recent launch of staking and the token's listing on new exchanges are driving bullish sentiment. Community members are drawn to the narrative of financial freedom and the potential for early retirement, creating a strong and dedicated holder base.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

ALDX is trending due to anticipation surrounding its upcoming FDA decision on its dry eye drug, reproxalap, with the community actively debating the likelihood of approval after previous setbacks. Discussions also involve the potential impact of a new RASP pipeline focus and a collaboration with AbbVie. Community members are weighing the potential for a short squeeze and a significant price movement based on the FDA's verdict.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's potential for a short squeeze is a key focus, with high short interest and rising borrowing costs fueling speculation. Additionally, the community is discussing Reddit's growth prospects relative to other social media platforms, specifically highlighting new advertising tools and earnings momentum. Some investors are anticipating inclusion in the S&P 500 as a potential catalyst.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as investors digest recent earnings and analyst upgrades, while navigating concerns about EMEA performance and margin compression. The community is debating whether the stock's pullback represents a buying opportunity amidst the AI-driven data center boom, or if it signals a broader correction. Discussions also involve the stock's potential inclusion in the S&P 500 and the impact of insider selling.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals is trending due to recent price volatility and community speculation about potential catalysts. Discussions revolve around its low float and potential for a short squeeze, with some eyeing it as a potential high-reward play. The stock's movements are also being compared to other recent high-flying low float stocks.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending due to positive community sentiment following Oppenheimer's raised price target and updates on the rezpegaldesleukin's Phase 2b REZOLVE-AA study.  Discussions revolve around the study's results in treating alopecia areata and its potential impact, with community members analyzing trial data and speculating on future performance. Some traders are pointing to Nektar as an attractive acquisition target within the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul class="summary-bullets"><li>According to the topline data, patients experienced statistical gains in mobility and function.</li><li>All enrolled subjects remained free from ongoing immunotherapies at the last follow-up, and none needed rescue interventions.&nbsp;</li><li>Based on this data, Kyverna plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2026.</li></ul>Kyverna Therapeutics, Inc. (KYTX) shares drew significant investor attention on Monday morning after the company announced promising outcomes from its registrational Phase 2 study of the experimental CAR T-cell therapy mivocabtagene autoleucel (miv-cel) in patients with stiff person syndrome.Stiff person syndrome is a rare and disabling autoimmune condition with no approved treatments.<h2 class="st-heading-2">Positive Trial Outcomes</h2>In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements in both primary and secondary disease measures. The 26 participants enrolled in the study were followed through the main analysis at 16 weeks, with additional observations continuing thereafter.According to the topline data, patients experienced statistical gains in mobility and function. For the primary timed 25-foot walk endpoint, median performance improved 46% compared with baseline, with 81% surpassing a clinically meaningful threshold.&nbsp;Following the trial outcome,&nbsp;<a href="https://stocktwits.com/symbol/KYTX">Kyverna’s stock</a> traded over 11% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;Secondary disability and stiffness indices also improved markedly. Among those who needed walking aids before therapy, two-thirds no longer required assistance by week 16.<h2 class="st-heading-2">Elimination Of Chronic Treatments</h2>All enrolled subjects remained free from ongoing immunotherapies at the last follow-up, and none needed rescue interventions.&nbsp;“Today’s topline data represent a significant breakthrough in the treatment of stiff person syndrome, demonstrating miv-cel’s ability to reverse progressive disability in a debilitating disease that has no approved therapies,” said Naji Gehchan, Chief Medical and Development Officer of Kyverna Therapeutics.&nbsp;Based on this data, Kyverna plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2026.KYTX shares have surged nearly 124% this year.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-goldman-sachs-downgrade-arm-holdings-stock/cLe4GDURE8v">Why Did Goldman Sachs Downgrade Arm Holdings Stock?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Senior Clinical Practice Facilitator Nicole Prescott administering breakthrough treatment to patient Katie Tinkler for lupus at University College London Hospital in London.

KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?

In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.

Equity

In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.


Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised shares of Kyverna Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, MarketBeat reports...

William Blair Brokers Increase Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Equities researchers at William Blair increased their FY2025 earnings estimates for Kyverna Therapeutics in a note issued to investors on...

FY2025 Earnings Forecast for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Kyverna Therapeutics in a report issued on Wednesday, November...

Kyverna Therapeutics (NASDAQ:KYTX) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat Ratings...

Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.89	--	--	N/A
Q3 '25	-$0.97	-$0.85	12.47%	BEAT
Q2 '25	-$1.04	-$0.97	7.08%	BEAT
Q1 '25	-$1.13	-$1.03	8.50%	BEAT
Q4 '24	-$0.84	-$0.87	-3.15%	MISSED

KYTX
Kyverna Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest KYTX News

KYTXKyverna Therapeutics Inc.